Medical device companies can spend considerable time preparing documentation, arranging testing and building quality management systems without first agreeing exactly what they need to achieve. The work may be technically sound, but if it is completed in the wrong order or based on an unconfirmed regulatory pathway, it may not support the intended route to market. Evidence may need to be supplemented, documents rewritten and development decisions revisited. A practical medical device regulatory strategy helps prevent this disconnect by establishing a clear route from the company’s current position to market entry, with decisions, activities and resources aligned around a common objective.
The purpose is not to produce another document that sits alongside the development plan. It is to help the company decide what to do, when to do it and why it matters. A useful strategy connects commercial ambitions with the intended purpose of the device, its classification, target markets, evidence requirements and quality management activities. It should also make the implications of those decisions visible to the people responsible for delivering the product. For founders, product leads and regulatory teams, that means a clearer understanding of priorities, a more realistic budget and fewer unexpected requirements emerging shortly before launch.
1. Start with What Your Company Wants to Achieve
A regulatory strategy should begin with the product and commercial objectives, rather than a list of documents to prepare. Before deciding which tests to commission or which procedures to implement, the company needs to establish what product it intends to place on the market, who will use it, for what purpose and in which patient population. The proposed claims are equally important. A device’s intended purpose and the benefits the company wants to communicate should provide a consistent foundation for classification, evidence planning and the eventual submission.
These questions should be considered alongside the practical circumstances of the business. Which markets offer the strongest commercial opportunity? When does the company hope to begin generating revenue? What funding, expertise and evidence are already available? The answers help distinguish what the organisation would ideally like to achieve from what it can realistically deliver within its current resources. A strategy that assumes access to funding, personnel or supporting data that the company does not yet have may appear complete on paper but provide little assistance with day-to-day decisions.
The company should also consider how the product or business may change over the next few years. Planned developments, broader claims or additional markets may affect the work worth undertaking now. This does not mean attempting to complete every future requirement before the first launch. It means understanding the direction of the business well enough to avoid decisions that create unnecessary rework later. When the commercial objective is clear, regulatory activities can be prioritised according to how they contribute to that objective, rather than simply because they appear on a generic compliance checklist.
2. Decide Which Market Should Come First
Whether to enter the UK, EU or US market first is a common question, but there is no single answer that is right for every medical device. The decision should reflect the device, its available regulatory pathways, the evidence already held and the commercial opportunity in each market. Choosing a route because it is familiar, or because it is assumed to be faster, can overlook important differences in the work required. A practical strategy compares the realistic options before the company commits its budget and launch plans.
That comparison should consider classification, the technical and clinical evidence needed, the expected cost and time involved, and whether certification body, Notified Body or FDA review is required. Local registration, representative and post-market requirements also need to be understood. These activities are part of market entry and ongoing supply, not administrative details to be addressed once the main submission is complete. The strategy should make them visible early enough for the company to allocate responsibility and resources.
Commercial demand must remain part of the decision. A market with an apparently straightforward regulatory route may not offer the strongest customer opportunity, while a more demanding route may be commercially justified. The first market should therefore support the company’s business priorities while creating a sensible foundation for later expansion. Where work completed for one market may support another, the strategy should identify that opportunity and assess what additional evidence or documentation would still be needed. The objective is not to assume that one submission can simply be reused elsewhere, but to plan development activities so that useful evidence is not unnecessarily duplicated.
3. Confirm the Regulatory Pathway Before Building the Documentation
Once the intended purpose and priority market are clear, the company can determine the device’s regulatory status, proposed classification and applicable conformity assessment or submission pathway. These decisions should be supported by a documented rationale rather than an informal assumption. They establish the basis for identifying the relevant regulatory requirements, standards, evidence and documentation. Without that foundation, a team can produce an extensive file while still missing the information needed for the route it ultimately has to follow.
The next step is to define the technical, pre-clinical and clinical evidence required to support the device. Depending on the product, this may also involve usability, software, cybersecurity or biological evaluation activities. These should be planned as connected parts of the development programme rather than commissioned independently. The strategy should explain what evidence already exists, what further work is required and which decisions must be settled before that work begins. This helps avoid arranging testing before the product requirements or proposed claims have been sufficiently defined.
Documentation should then be developed around the confirmed pathway and evidence plan. The required submission structure, external reviews, registrations and economic operators should be identified so that the company understands the complete route, not just the next deliverable. Consistency across the file is essential. The intended purpose, product description, claims and supporting evidence should remain aligned as different teams contribute to the documentation. A practical strategy gives those teams a shared basis for their work and reduces the risk of discovering conflicting assumptions during final review. The measure of progress is not how many documents have been completed, but whether the necessary evidence and decisions are in place to support market entry.
4. Plan When the QMS and ISO 13485 Activities Are Needed
Quality management system planning should form part of the regulatory strategy from the beginning. However, the appropriate timing and scope of ISO 13485 activities depend on the target market, regulatory pathway, company activities and stage of development. Whether certification is required should be assessed for the intended route rather than assumed. The strategy should distinguish between establishing the processes needed to control current development work and preparing the organisation for any later certification or external assessment.
Design and development controls deserve particular attention because the records generated during development may be needed to support the finished device. Leaving these processes until late in the project can mean that important decisions, reviews or testing records are missing or have to be reconstructed. Supplier arrangements and outsourced processes also need to be considered at the point when they become relevant. A quality system introduced shortly before submission cannot automatically resolve gaps in how earlier work was controlled or recorded.
The opposite approach can also create problems. Implementing an unnecessarily large system at an early stage may consume time and budget without helping the company reach its next development milestone. A staged approach allows the organisation to introduce the processes it needs as activities become relevant, while still planning for certification and commercial supply. That plan should include the timing of internal audits and management reviews, alongside arrangements for complaints, vigilance, corrective and preventive action, and post-market activities. The aim is a quality management system that develops with the business, supports the evidence being generated and is ready for the responsibilities that follow launch.
5. Turn the Strategy into a Practical, Controlled Plan
A regulatory strategy becomes useful when it is translated into a plan that people can follow. It should identify the main activities and deliverables, the order in which they need to be completed and the dependencies between design, testing, clinical, quality and regulatory work. Each activity should have a clear owner, and decisions requiring specialist or external input should be identified early. This makes it easier to distinguish work that can progress immediately from work that depends on an unresolved requirement, design decision or evidence gap.
Timelines and costs should reflect those dependencies. A target submission date is not, on its own, a plan for achieving submission readiness. The company needs to understand which activities determine that date, where external review is involved and what could delay progress. Review points should give the team opportunities to assess whether the original assumptions remain valid. The main regulatory risks should also be recorded, together with how they will be managed, so that uncertainty is considered before it becomes an urgent problem.
The plan should remain controlled and current throughout the project. Changes to the product, evidence, intended market or business priorities may affect classification, documentation, testing or the sequence of work. Updating the strategy at these points helps the company avoid continuing with activities that no longer support its objectives. It also gives leadership, technical, clinical and quality teams a shared view of what has changed and what needs to happen next.
A well-developed strategy cannot remove every review period or guarantee approval. Its value lies in reducing avoidable delays, inconsistent documentation, repeated testing, audit nonconformities and costly rework. By helping the company make decisions at the right time and focus its resources on the right activities, it can support a more efficient route to market and an earlier opportunity to begin generating revenue. Regulatory strategy should facilitate progress, not create another layer of administration.
LFH supports medical device companies in bringing regulatory strategy, evidence planning and quality management together. Whether you are defining the route for a new product, preparing for market entry or reviewing an existing development programme, our team can help clarify the requirements, identify gaps and establish a practical sequence of work. Speak to LFH about medical device compliance support that reflects your product, target markets and commercial priorities.
FAQs – Medical Device Regulatory Strategy
What is a medical device regulatory strategy?
A medical device regulatory strategy defines how a company will move from its current development stage to market entry. It connects the product’s intended purpose, classification, target markets, evidence requirements, quality management activities and submission pathway within a practical plan.
When should a company develop its regulatory strategy?
The strategy should be established before the company commits substantial resources to documentation, testing or quality system implementation. Early planning helps ensure that these activities support the intended product, claims and target market, rather than having to be revised later.
Should a medical device company enter the UK, EU or US first?
There is no universally correct first market. The decision should consider classification, available pathways, existing evidence, review requirements, costs and commercial demand. It should also assess whether work completed for the first market can support later expansion.
Is a regulatory strategy the same as technical documentation?
No. Technical documentation contains the information and evidence needed to support the device. The regulatory strategy determines what work is required, how it fits the chosen pathway and the order in which it should be completed. It guides the development of the documentation rather than replacing it.
When should ISO 13485 be considered?
ISO 13485 and quality management system planning should be considered when establishing the regulatory strategy. The timing of implementation and any certification depends on the market, pathway and company activities. Processes needed to generate controlled development records should not be left until the end of the project.
Should a regulatory strategy be updated after it has been agreed?
Yes. The strategy should be reviewed when the product, evidence, target market or business priorities change. Updates help keep the development plan, regulatory activities and commercial objectives aligned.
Can a regulatory strategy guarantee approval or a launch date?
No. Regulatory strategy cannot guarantee approval or eliminate external review periods. It can help reduce avoidable delays by identifying requirements, evidence gaps, responsibilities and dependencies before they disrupt the project.
